| P2093 | author name string | Margaret R Hammerschlag | |
| | Jens Boman | |
| P2860 | cites work | Distribution of Chlamydia pneumoniae infection in the athersclerotic carotid artery | Q37881215 |
| | Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. | Q37881308 |
| | Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease | Q37881317 |
| | The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production | Q37881386 |
| | Antibody response to Chlamydia pneumoniae infection in children with respiratory illness | Q37881439 |
| | Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model | Q37881464 |
| | Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. | Q37881682 |
| | Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery | Q37882074 |
| | Chronic infections and coronary heart disease: is there a link? | Q37882245 |
| | Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group | Q37882250 |
| | Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis | Q37882356 |
| | Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction | Q37882420 |
| | Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction | Q37882562 |
| | Infection and coronary heart disease | Q37882569 |
| | Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen | Q37882581 |
| | Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves | Q37883146 |
| | Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms | Q37883353 |
| | Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection | Q37883374 |
| | High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement | Q37883688 |
| | Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group | Q37883953 |
| | Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease | Q37884972 |
| | Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland | Q37885075 |
| | Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy | Q37885296 |
| | Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery | Q37886058 |
| | Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. | Q37886690 |
| | Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. | Q37886996 |
| | Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture | Q37887150 |
| | Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia | Q37888689 |
| | Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators | Q37890128 |
| | Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain | Q37890285 |
| | Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men | Q29619308 |
| | Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae | Q31713580 |
| | Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment | Q31829380 |
| | Nucleotide sequence and taxonomic value of the major outer membrane protein gene of Chlamydia pneumoniae IOL-207. | Q33545301 |
| | Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies | Q33588103 |
| | Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease | Q33762172 |
| | Molecular diagnosis of Chlamydia pneumoniae infection. | Q33775972 |
| | The role of Chlamydia pneumoniae in cardiovascular disease | Q33817488 |
| | Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses | Q33910496 |
| | Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review | Q33925828 |
| | Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells | Q33935030 |
| | Antibiotics in the prevention and treatment of coronary heart disease | Q33935098 |
| | Chlamydia pneumonia (and other infective agents) in atherosclerosis and acute coronary syndromes. How good is the evidence? | Q33937618 |
| | Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR | Q33970537 |
| | Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens | Q33971158 |
| | Comparison of five serologic tests for diagnosis of acute infections by Chlamydia pneumoniae | Q33998580 |
| | Detection of Chlamydia pneumoniae DNA and antigen in the circulating mononuclear cell fractions of humans and koalas | Q34004325 |
| | The use of serologic tests for the diagnosis of chlamydial infections | Q34067823 |
| | Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old) | Q34086738 |
| | Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma | Q34121913 |
| | Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). | Q34312881 |
| | Can acute Chlamydia pneumoniae respiratory tract infection initiate chronic asthma? | Q34479396 |
| | A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia | Q35138146 |
| | Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease | Q35371043 |
| | In vitro activity of a group of broad-spectrum cephalosporins and other beta-lactam antibiotics against Chlamydia trachomatis | Q35740197 |
| | Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis | Q35764383 |
| | Infectious agents are not necessary for murine atherogenesis | Q36368432 |
| | Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms | Q36541516 |
| | A seroepidemiologic study of Chlamydia pneumoniae in Rhode Island. Evidence of serologic cross-reactivity | Q37890729 |
| | Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries | Q37891287 |
| | Specificity of the microimmunofluorescence assay for the serodiagnosis of Chlamydia pneumoniae infections | Q37892198 |
| | Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques | Q37892518 |
| | Association of Prior Infection With Chlamydia pneumoniae and Angiographically Demonstrated Coronary Artery Disease | Q37892814 |
| | Chronic Chlamydia pneumoniae Infection as a Risk Factor for Coronary Heart Disease in the Helsinki Heart Study | Q37893723 |
| | Persistent infection with Chlamydia pneumoniae following acute respiratory illness | Q37893923 |
| | Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease | Q37894988 |
| | Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections | Q37895800 |
| | A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. | Q37896793 |
| | Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction | Q37899465 |
| | Quinolones in Sexually Transmitted Diseases | Q40489389 |
| | Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae | Q42729698 |
| | Coronary heart disease and Chlamydia pneumoniae DNA in blood mononuclear cells | Q43426679 |
| | Chlamydia pneumoniae in vascular tissues from heart-transplant donors | Q43429587 |
| | Significance of Chlamydia pneumoniae (TWAR) in atherosclerotic lesions | Q43432055 |
| | Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin | Q47330818 |
| | Cellular pathology. As based upon physiological and pathological histology. Lecture XVI--Atheromatous affection of arteries. 1858. | Q48526126 |
| | Infections and atherosclerosis: new clues from an old hypothesis? | Q53565811 |
| | Enterovirus infections as a possible risk factor for myocardial infarction | Q64381784 |
| | Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial | Q71512983 |
| | The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment | Q73052815 |
| | Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? | Q74561877 |
| | Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study | Q37878753 |
| | Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease | Q37878785 |
| | Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction | Q37878896 |
| | Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease | Q37878909 |
| | Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts | Q37879001 |
| | Antibiotics and risk of subsequent first-time acute myocardial infarction | Q37879181 |
| | The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery | Q37879200 |
| | Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease | Q37879484 |
| | Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients. | Q37879706 |
| | Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children | Q37879880 |
| | Chlamydia pneumoniae in coronary and iliac arteries of Japanese patients with atherosclerotic cardiovascular diseases | Q37879945 |
| | In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries. | Q37880155 |
| | Failure to detect Chlamydia pneumoniae in calcific and degenerative arteriosclerotic aortic valves excised during open heart surgery. | Q37880226 |
| | Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis | Q37880332 |
| | Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction | Q37880581 |
| | High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. | Q37880679 |
| | Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients. | Q37880753 |
| | In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. | Q37880865 |
| | Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease | Q37881093 |
| | Failure to demonstrate Chlamydia pneumoniae in symptomatic abdominal aortic aneurysms by a nested polymerase chain reaction (PCR). | Q37881207 |
| | Chlamydia pneumoniae in human abdominal aortic aneurysms | Q37881211 |
| | Serological cross-reactions between Bartonella and Chlamydia species: implications for diagnosis | Q36546292 |
| | Interference of immunoglobulin G (IgG) antibodies in IgA antibody determinations of Chlamydia pneumoniae by microimmunofluorescence test | Q37073869 |
| | Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline | Q37093492 |
| | Age-related interference with Chlamydia pneumoniae microimmunofluorescence serology due to circulating rheumatoid factor | Q37120590 |
| | Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications | Q37214056 |
| | Chlamydia pneumoniae in atheroma: consideration of criteria for causality | Q37228857 |
| | The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring IgG antibodies against Chlamydia pneumoniae | Q37230432 |
| | Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis | Q37346172 |
| | The mechanisms by which infectious agents may contribute to atherosclerosis and its clinical manifestations | Q37867657 |
| | Ultrastructural study of Chlamydia pneumoniae in a continuous-infection model | Q37873353 |
| | Detection of Chlamydia pneumoniae DNA in CD3+ lymphocytes from healthy blood donors and patients with coronary artery disease | Q37875345 |
| | Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults : the Cardiovascular Health Study | Q37875347 |
| | Picornavirus proteins share antigenic determinants with heat shock proteins 60/65. | Q37875396 |
| | Comparative analysis of the putative amino acid sequences of chlamydial heat shock protein 60 and Escherichia coli GroEL. | Q37875453 |
| | The effect of chronic azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease | Q37875535 |
| | Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study | Q37875542 |
| | Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leukocytes | Q37875681 |
| | Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection? | Q37875724 |
| | Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction | Q37875878 |
| | Frequency of serological evidence of Bordetella infections and mixed infections with other respiratory pathogens in university students with cough illnesses | Q37875976 |
| | Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study | Q37876040 |
| | Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae | Q37876262 |
| | Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis | Q37876300 |
| | Description and status of the azithromycin and coronary events study (ACES). | Q37876308 |
| | Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial | Q37876312 |
| | Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction | Q37876368 |
| | Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic tissue | Q37876378 |
| | Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results | Q37876389 |
| | The microimmunofluorescence test for Chlamydia pneumoniae infection: technique and interpretation | Q37876392 |
| | Isolation and continuous growth of Chlamydia pneumoniae from arterectomy specimens | Q37876438 |
| | Evaluation of a commercial test for antibodies to the chlamydial lipopolysaccharide (Medac) for serodiagnosis of acute infections by Chlamydia pneumoniae (TWAR) and Chlamydia psittaci | Q37876797 |
| | The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies. | Q37876824 |
| | Association of serology with the endovascular presence of Chlamydia pneumoniae and cytomegalovirus in coronary artery and vein graft disease | Q37877190 |
| | Chlamydia pneumoniae does not influence atherosclerotic plaque behavior in patients with established carotid artery stenosis | Q37877209 |
| | Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection | Q37877400 |
| | Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease | Q37877457 |
| | Chlamydia pneumoniae eradication from carotid plaques. Results of an open, randomised treatment study | Q37877463 |
| | Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model? | Q37877470 |
| | Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women | Q37877649 |
| | Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease | Q37877691 |
| | In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model | Q37877849 |
| | Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease | Q37877922 |
| | Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study | Q37878104 |
| | Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction. | Q37878157 |
| | Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque | Q37878316 |
| | Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study | Q37878617 |
| | Detection of Chlamydia pneumoniae DNA in atheromatous tissues by polymerase chain reaction | Q37878712 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| | Chlamydia pneumoniae | Q62869737 |
| P304 | page(s) | 1-20 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Clinical Microbiology Reviews | Q5133777 |
| P1476 | title | Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies | |
| P478 | volume | 15 | |